|
HALO Halozyme Therapeutics Inc 1159036 |
| Balance Sheet |
|
Current Assets
|
1,126,976,000 |
|
Assets
|
2,118,030,000 |
|
Current Liabilities
|
108,815,000 |
|
Liabilities
|
1,665,327,000 |
|
Equity
|
452,703,000 |
| Cash Flow Statement |
|
Operating Cash Flow
|
300,597,000 |
|
Investing Cash Flow
|
-292,203,000 |
| Market Analysis |
|
Price
|
54.80 |
|
BVPS
|
15.60 |
|
PB
|
3.51 |
|
PS
|
2.49 |
|
FCF
|
8,394,000 |
|
| Earnings |
|
| Oct |
Nov |
Dec |
| 10/31 |
1.08 |
11/04 |
|
|
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view HALO documents filed with the SEC.
HALO Filings
Clear
